Claimed effect · Teduglutide

Does Teduglutide help with reduced parenteral support in short bowel syndrome?

A
Grade A — established in humans1 phase 3 RCT (STEPS, n=86, 24 wk) · effect size: moderate
Short answerEstablished in humans. 1 phase 3 RCT (STEPS, n=86, 24 wk) point the same way: a moderate effect. STEPS randomised 86 adults dependent on parenteral support to daily teduglutide or placebo. The response endpoint — a 20–100% reduction in weekly parenteral volume at weeks 20 and 24 — was reached by 63% against 30% on placebo.

What the studies show

STEPS randomised 86 adults dependent on parenteral support to daily teduglutide or placebo. The response endpoint — a 20–100% reduction in weekly parenteral volume at weeks 20 and 24 — was reached by 63% against 30% on placebo.

“There were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (13/43 [30%]; P = .002).”

Verbatim, from the abstractJeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS). Gastroenterology, 2012;143:1473–1481

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

Teduglutide is a 33-amino-acid analogue of glucagon-like peptide-2, approved since 2012 as Gattex in the US and Revestive in the EU for short bowel syndrome in people dependent on parenteral support. In the pivotal STEPS trial, 63% of treated patients reduced their intravenous feeding volume against 30% on placebo over 24 weeks. It is given by daily subcutaneous injection and is prescription-only everywhere LYO covers.

Teduglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Teduglutide proven to help with reduced parenteral support in short bowel syndrome?
Yes, as far as human trials can show it: 1 phase 3 RCT (STEPS, n=86, 24 wk). LYO grades this outcome A.
What studies are behind the grade?
STEPS randomised 86 adults dependent on parenteral support to daily teduglutide or placebo. The response endpoint — a 20–100% reduction in weekly parenteral volume at weeks 20 and 24 — was reached by 63% against 30% on placebo.
Is Teduglutide approved for this?
Teduglutide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Teduglutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →